Highest-materiality recent filing
CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock
Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.
CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit
Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.
CytoDyn agrees to settle securities class action for $500K cash and 49M shares
Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.
CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months
Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination
Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.
CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%
52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.
CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway
Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.
CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue
Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.
CytoDyn appoints Jacob Lalezari as permanent CEO, names Mitchell Cohen interim CFO
Jacob Lalezari appointed CEO effective Jan 26, 2024; previously interim CEO since Nov 2023.
Partial clinical hold from March 2022 lifted by FDA in December 2023.
Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.
CytoDyn shareholders approve authorized common stock increase to 1.75B shares
Authorized shares increased from 1.35B to 1.75B, approved by 504.7M for vs 42.6M against.
CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability
FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.
CytoDyn discloses unregistered equity sales raising ~$3.5M with heavy dilution
Converted $2.0M of convertible note principal into ~9.8M shares via exchange; relied on Section 3(a)(9).
CytoDyn CEO resigns, returns as SVP; files $100M+ claim against former CRO Amarex
Dr. Cyrus Arman resigned as President and PEO on July 6, 2023; returns as SVP Business Operations with reduced salary of $300k.
CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed
Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.
CytoDyn raises $4.9M through private placement of 21.3M units at $0.23/unit
Proceeds of ~$4.9M from sale of ~21.3M units, each unit one share plus one warrant to purchase one share.
CytoDyn CMO Scott A. Kelly resigns effective immediately
Scott A. Kelly, M.D., resigns as Chief Medical Officer of CytoDyn on December 19, 2022.
Extends Indemnitors' surety bond obligation to Jan 31, 2023; must relieve $1.5M cash collateral by Jan 5, 2023, remaining $5M by Jan 31.
CytoDyn CTO Nitya G. Ray resigns effective November 21, 2022
Nitya G. Ray, Ph.D., resigned as Chief Technology Officer effective immediately on November 21, 2022.
CytoDyn withdraws BLA for leronlimab in HIV-MDR citing CRO data issues
Voluntarily withdrew pending BLA for leronlimab as HIV combination therapy; FDA approval deemed not feasible due to CRO data quality issues.
Shareholders approve increase in CytoDyn authorized shares from 1B to 1.35B
Stockholders voted 522,967,334 for, 19,601,702 against, 1,058,601 abstentions.
CytoDyn restates FY2021 and five quarterly periods; prior financials no longer reliable
Audit Committee concludes FY2021 annual and five quarterly periods should not be relied upon.
CytoDyn raises $21.8M in private placement of units; corrects warrant exercise price to $0.30
Raised $21.8M gross via 85.4M units at $0.255/unit; each unit = one share + 0.75 warrant.
CytoDyn raises $21.8M in private placement; appoints Cyrus Arman as President
Raised ~$21.8M gross via ~85.4M units at $0.255/unit; each unit = 1 share + 3/4 warrant (5-yr term).
CytoDyn raises ~$8.8M in private placement of 34.6M units with warrants
Raised $8,834,500 gross from ~34.6M units (1 share + 0.75 warrant) via placement agent.
CytoDyn settles former CMO suit, grants 8.3M shares & 7M warrants; board member resigns
Settlement with former CMO Richard Pestell resolves breach-of-contract lawsuit; CytoDyn relinquishes 8,342,000 shares and removes transfer restrictions.
CytoDyn raises ~$6.5M in unregistered equity offerings
Received subscription agreements for ~24.4M units (1 share + 3/4 warrant) from accredited investors via placement agent.
CytoDyn raises $4.8M via private placement of 17.6M units at 85% of VWAP
Issued 107,707 shares to former exec for $36,671 in severance satisfaction.
CytoDyn auditor Warren Averett resigns; MGO appointed as new auditor
Warren Averett resigned as CytoDyn's independent auditor effective April 13, 2022; audit committee did not recommend change.
On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).
On January 26, 2024, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s Chief Executive Officer and will serve as its principal executive officer, effective as of January 26, 2024.
On January 10, 2024, the Company entered into an agreement with Rapid Deployment LLC d/b/a InterimExecs (“InterimExecs”), under which Mitchell Cohen will serve as the Company’s Interim CFO, effective February 1, 2024.
On January 23, 2024, Antonio Migliarese informed the Company that he would be resigning from his position as CFO, effective January 31, 2024.
On November 17, 2023, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with. Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s interim CEO on an at-will basis, effective November 17, 2023.
Antonio Migliarese, who was appointed as interim President on May 18, 2023, ceased being interim President on November 17, 2023, but will continue in his roles of Chief Financial Officer and Treasurer, as well as serving as the Company’s principal accounting officer.
Dr. Cyrus Arman, on medical leave since May 18, 2023, after serving as the President and principal executive officer of CytoDyn Inc. (the “Company”) since July 9, 2022, resigned as the Company’s President and principal executive officer on July 6, 2023, and returned to the Company as its Senior Vice President, Business Operations, a nonexecutive position in which he will work reduced hours, effective July 7, 2023.
On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.
Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.
On December 19, 2022, the Company and Scott A. Kelly M.D., the Company’s Chief Medical Officer, agreed that Dr. Kelly will resign from his role at the Company, effective immediately.
On November 21, 2022, the Company and Nitya G. Ray, Ph.D., the Company’s Chief Technology Officer, agreed that Dr. Ray will resign from his role at the Company, effective immediately.
On October 13, 2022, the Company’s Board of Directors (the “Board”) approved the appointment of Stephen M. Simes (“Mr. Simes”) as a director of the Company, effective October 13, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material